felbamate
Sign in to saveAlso known as ADD 03055, Felbatol®, W 554, carbamic acid 2-phenyltrimethylene ester, Carbamic acid 2-phenyltrimethylene ester, Felbamato, Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester, Felbamatum
Felbamate (marketed under the brand name Felbatol by MedPointe) is an anticonvulsant used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox–Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drug's usage to severe refractory epilepsy.
Key facts
- Drug.verifiedrevid
- 461099211
- Drug.IUPAC_name
- (3-carbamoyloxy-2-phenylpropyl) carbamate
- Drug.image
- Felbamate.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 225
- Drug.tradename
- Felbatol
- Drug.MedlinePlus
- a606011
- Drug.pregnancy_US
- C
- Drug.legal_status
- Rx-only
- Drug.routes_of_administration
- By mouth (tablets, oral suspension)
- Drug.bioavailability
- >90%
- Drug.metabolism
- Hepatic
- Drug.elimination_half life
- 20–23 hours
- Drug.IUPHAR_ligand
- 5473
- Drug.CAS_number
- 25451-15-4
- Drug.ATC_prefix
- N03
- Drug.ATC_suffix
- AX10
- Drug.PubChem
- 3331
via Wikipedia infobox
Research
799 papers- Felbamate.2006
- Felbamate.2012
- Felbamate.Seminars in pediatric neurology · 1997
- Felbamate add-on therapy for drug-resistant focal epilepsy.The Cochrane database of systematic reviews · 2022
- Felbamate.2026
via PubMed
~4 min read
Encyclopedic overview
11 sectionsContents
- Mechanism of action
- Approval history
- United States
- United Kingdom
- Indications and usage
- Dosing
- Side effects
- Drug interactions
- History
- References
- External links
Felbamate (marketed under the brand name Felbatol by MedPointe) is an anticonvulsant used in the treatment of epilepsy. It is used to treat partial seizures (with and without generalization) in adults and partial and generalized seizures associated with Lennox–Gastaut syndrome in children. However, an increased risk of potentially fatal aplastic anemia and/or liver failure limit the drug's usage to severe refractory epilepsy.
==Mechanism of action== Felbamate has been proposed to have a unique dual mechanism of action as a positive modulator of GABAA receptors and as a blocker of NMDA receptors, particularly isoforms containing the NR2B subunit. Although it is clear that felbamate does cause pharmacological inhibition of NMDA receptors, the relevance of NMDA receptor blockade as a strategy for the treatment of human epilepsy has been questioned. Therefore, the importance of the effects of felbamate on NMDA receptors to its therapeutic action in epilepsy is uncertain.
Excerpted from Wikipedia’s “felbamate” article, available under the CC BY-SA 4.0 licence.